When Mesothelioma Comes Back, Treatment Options Can Still Exist

A case report published in June 2026 in the medical journal Cureus titled “Long-Term Disease Control With Second-Line Nivolumab Monotherapy in Malignant Pleural Mesothelioma,” documents an unusually positive outcome for a patient battling malignant pleural mesothelioma, the asbestos-caused cancer of the lining of the lung.

The patient, a 72-year-old man whose asbestos exposure came from years of work in shipbuilding, ironworks, and construction, had already been through a great deal. He underwent major surgery to remove the affected lung and pleura (an extrapleural pneumonectomy), followed by chemotherapy with cisplatin and pemetrexed. When the cancer returned and spread to his lymph nodes and chest wall despite additional chemotherapy, his doctors turned to immunotherapy — a drug called nivolumab that helps the body’s own immune system recognize and attack cancer cells.

The results were remarkable. The patient’s tumors shrank dramatically, with near-complete disappearance of the cancer in his lymph nodes and chest wall. He remained free of disease progression for two full years and tolerated the treatment well, avoiding the serious side effects that can accompany other immunotherapy combinations.

What makes this case meaningful is its context. For patients whose mesothelioma returns after chemotherapy, lasting responses to second-line immunotherapy have historically been uncommon, with benefit in large clinical trials typically measured in just a few months. This patient’s two years of disease control stands out as an exceptional result, which his doctors suggest may reflect factors like a lower tumor burden after surgery. Not every patient will respond this way — but the case adds to a growing body of evidence that meaningful mesothelioma treatment options, and real reasons for hope, can continue to exist even after initial therapies stop working.